To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
-
Travere Investigational Site, Los Angeles, California, United States, 90048
Travere Investigational Site, Wilmington, Delaware, United States, 19803
Travere Investigational Site, Miami, Florida, United States, 33136
Travere Investigational Site, Miami, Florida, United States, 33155
Travere Investigational Site, Iowa City, Iowa, United States, 52242
Travere Investigational Site, Boston, Massachusetts, United States, 02111
Travere Investigational Site, Ann Arbor, Michigan, United States, 48109-5008
Travere Investigational Site, Minneapolis, Minnesota, United States, 55454
Travere Investigational Site, Kansas City, Missouri, United States, 64108
Travere Investigational Site, Hackensack, New Jersey, United States, 07601
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
1 Year to 17 Years
ALL
No
Travere Therapeutics, Inc.,
Radko Komers, MD, PhD, STUDY_DIRECTOR, Travere Therapeutics, Inc.
2025-06-01